Koyfin Home > Directory > Health Care > Apellis Pharmaceuticals Inc > Preferred Equity

Apellis Pharmaceuticals Inc Preferred Equity Chart (APLS)

Apellis Pharmaceuticals Inc annual/quarterly Preferred Equity from 2016 to 2017.
  • Apellis Pharmaceuticals Inc Preferred Equity for the quarter ending September 09, 2017 was $112m a 17.66% increase of 20m year over year
  • Apellis Pharmaceuticals Inc Preferred Equity for the last 12 months ending September 09, 2017 was $112m a 17.66% increase of 20m year over year
  • Apellis Pharmaceuticals Inc Annual Preferred Equity for 2016 was $92m a 16.15% increase of 15m from 2015
  • Apellis Pharmaceuticals Inc Annual Preferred Equity for 2015 was $77m
Other Balance Sheet Metrics:
  • Apellis Pharmaceuticals Inc Total Assets for the quarter ending September 09, 2018 was $239m a 23.84% increase of 57m year over year
  • Apellis Pharmaceuticals Inc Other Liabilities for the quarter ending December 12, 2018 was $0m a -57.45% decrease of 0m year over year
  • Apellis Pharmaceuticals Inc Total Equity for the quarter ending September 09, 2018 was $196m a 23.99% increase of 47m year over year
View Chart On Koyfin

Quarterly APLS Preferred Equity Data

09/2017$112m
06/2017$92m
03/2017$92m
12/2016$92m
03/2016$77m

Annual APLS Preferred Equity Data

2016$92m
2015$77m